Abbvie Rinvoq Phase 3 Study Shows Continued Repigmentation Through Week 76
AbbVie's Phase 3 studies for Rinvoq (upadacitinib) have demonstrated continued repigmentation in participants through week 76.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.